Ardelyx, Inc. (ARDX)
3.74
-0.15
(-3.86%)
USD |
NASDAQ |
Aug 24, 16:00
3.76
+0.02
(+0.53%)
After-Hours: 20:00
Ardelyx EPS Diluted (Quarterly) : -0.0674 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.0674 |
| March 31, 2026 | -0.153 |
| December 31, 2025 | -0.0017 |
| September 30, 2025 | -0.004 |
| June 30, 2025 | -0.0795 |
| March 31, 2025 | -0.1724 |
| December 31, 2024 | 0.019 |
| September 30, 2024 | -0.0034 |
| June 30, 2024 | -0.0702 |
| March 31, 2024 | -0.1138 |
| December 31, 2023 | -0.124 |
| September 30, 2023 | 0.0291 |
| June 30, 2023 | -0.0796 |
| March 31, 2023 | -0.1293 |
| December 31, 2022 | 0.0552 |
| September 30, 2022 | -0.1387 |
| June 30, 2022 | -0.1851 |
| March 31, 2022 | -0.2144 |
| December 31, 2021 | -0.3144 |
| September 30, 2021 | -0.4185 |
| June 30, 2021 | -0.4517 |
| March 31, 2021 | -0.3412 |
| December 31, 2020 | -0.3174 |
| September 30, 2020 | -0.2026 |
| June 30, 2020 | -0.2802 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.2517 |
| December 31, 2019 | -0.2834 |
| September 30, 2019 | -0.3746 |
| June 30, 2019 | -0.4065 |
| March 31, 2019 | -0.418 |
| December 31, 2018 | -0.4486 |
| September 30, 2018 | -0.3887 |
| June 30, 2018 | -0.42 |
| March 31, 2018 | -0.36 |
| December 31, 2017 | 0.21 |
| September 30, 2017 | -0.44 |
| June 30, 2017 | -0.54 |
| March 31, 2017 | -0.59 |
| December 31, 2016 | -0.66 |
| September 30, 2016 | -0.65 |
| June 30, 2016 | -0.83 |
| March 31, 2016 | -0.70 |
| December 31, 2015 | -0.65 |
| September 30, 2015 | -0.70 |
| June 30, 2015 | 0.42 |
| March 31, 2015 | -0.19 |
| December 31, 2014 | -0.21 |
| September 30, 2014 | 0.0039 |
| June 30, 2014 | 0.18 |
| March 31, 2014 | -0.18 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| REGENXBIO, Inc. | 0.4283 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -16.72M |
| Revenue (Quarterly) | 120.88M |
| Total Expenses (Quarterly) | 137.60M |
| Enterprise Value | 906.17M |
| Gross Profit Margin (Quarterly) | 94.74% |
| Profit Margin (Quarterly) | -13.83% |
| Earnings Yield | -6.05% |
| Normalized Earnings Yield | -6.043 |